Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set

Transfusion

Volumn 45, Issue 9, 2005, Pages 1443-1452

  Janetzko, Karin ^a   Cazenave, Jean Pierre ^b   Klüter, Harald ^b   Kientz, Daniel ^b   Michel, Martine ^b   Beris, Photis ^b   Lioure, Bruno ^b   Hastka, Jan ^b   Marblie, Stephane ^b   Mayaudon, Veronique ^b   Lin, Lily ^b   Lin, Jin Sying ^b   Conlan, Maureen G ^b   Flament, Jocelyne ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; ANTIBODY; PSORALEN DERIVATIVE; S 59, PSORALEN; S-59, PSORALEN;

ADULT; AGED; ANTIBODY DETECTION; APHERESIS; ARTICLE; BACTEREMIA; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FEVER; HUMAN; LONGITUDINAL STUDY; LYMPHOCYTOTOXICITY; MALE; PHASE 3 CLINICAL TRIAL; PHOTOCHEMISTRY; PROCESS OPTIMIZATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; REGRESSION ANALYSIS; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; ULTRAVIOLET A RADIATION; VOMITING; BACTERIAL INFECTION; BLEEDING; COMPARATIVE STUDY; ERYTHROCYTE TRANSFUSION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION;

ADULT; AGED; ANTIBODIES; BACTERIAL INFECTIONS; BLOOD COMPONENT REMOVAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMISTRY; PLATELET COUNT; PLATELET TRANSFUSION; PSORALENS; THROMBOCYTOPENIA; ULTRAVIOLET RAYS;

EID: 26944442457     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.00550.x     Document Type: Article

References (28)

1. Perez P, Salmi LR, Follea G, et al. Determinants of transfusion- associated bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion 2001;41:862-72.
2. Serious hazards of transfusion: annual report 2000-2001 [Internet]. Manchester: SHOT; 2002 Apr 9 [accessed 2005 Jan 31]. Available from: http://www.shotuk.org/SHOT%20Report%2000-01.pdf
3. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
4. Hei DJ, Grass J, Lin L, et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999;39:239-48.
5. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180-8.
6. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999;93:3140-7.
7. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000;78:209-16.
8. Lin L, Alfonso R, Behrman B, et al. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Infus Ther Transfus Med 1998;25:39-48.
9. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000;79:206-14.
10. Janetzko K, Klinger M, Mayaudon V, et al. Storage characteristics of split double-dose platelet concentrates derived from aphaeresis and treated with amotosalen hydrochloride and UVA light for pathogen inactivation. Infus Ther Transfus Med 2002;29:193-8.
11. Janetzko K, Lin L, Eichler H, et al. Implementation of INTERCEPT Blood System for platelets into routine blood bank manufacturing procedures: evaluation of aphaeresis platelets. Vox Sang 2004;86:239-45.
12. van Rhenen DJ, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
13. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation. The SPRINT Trial. Blood 2004;104:1534-41.
14. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Brussels: European Commission; 1993.
15. Clinical investigation of medical devices for humans. Harmonised standard EN 540. Brussels: European Commission; 1993.
16. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
17. Fuller TC, Phelan DL, Gebel HM, et al. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation 1982;34:24-9.
18. MedDRA introductory guide. Version 3.3. Reston, VA: MedDRA MSSO; 2002 Dec.
19. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997;337:1861-9.
20. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-7.
21. Bishop JF, Matthews JP, McGrath K, et al. Factors influencing 20-hour increments after platelet transfusion. Transfusion 1991;31:392-6.
22. Ishida A, Handa M, Wakui M, et al. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - a prospective analysis. Transfusion 1998;38:839-47.
23. Davis KB, Slichter SJ, Corash L. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 1999;39:586-92.
24. Cazenave JP, Davis K, Corash L. Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology. Semin Hematol 2001;38(Suppl 11):46-54.
25. Enright H, Davis K, Gernheimer T, et al. Factors influencing moderate to severe reaction to PLT transfusion: experience of the TRAP multicenter clinical trial. Transfusion 2003;43:1545-52.
26. Sarkodee-Adoo CB, Kendall JM, Sridhara R, et al. The relationship between the duration of platelet storage and the development of transfusion reactions. Transfusion 1998;38:229-35.
27. Hartwig D, Klüter H. Febrile and allergic reactions after transfusion of platelet concentrates. Transfus Med Hemother 2003;30:277-82.
28. Rebulla P. Refractoriness to platelet transfusion. Curr Opin Hematol 2002;9:516-20.